Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

NCT04700449 is registered in ClinicalTrials.gov with Connect Biopharm LLC as lead sponsor.

NCT NCT04700449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04700449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
Lead sponsor
Connect Biopharm LLC
Phase
Phase 2
Overall status
Completed
Start date
February 27, 2019
Completion date
November 10, 2022
Enrollment
145 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe ulcerative colitis